Patents by Inventor Michael Skynner
Michael Skynner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970555Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: GrantFiled: November 12, 2021Date of Patent: April 30, 2024Assignee: BicycleTx LimitedInventors: Ellen Gowans, Gemma Elizabeth Mudd, Michael Rigby, Punit Seth, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Publication number: 20240108737Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.Type: ApplicationFiled: January 10, 2022Publication date: April 4, 2024Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
-
Patent number: 11946041Abstract: The invention relates to a method for screening a library of peptide ligands, said library comprising a plurality of polypeptides covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of displaying said library of peptide ligands in a genetic display system, wherein the polypeptide comprises two or more reactive groups which form a covalent linkage to the molecular scaffold, and at least one loop which comprises a sequence of amino acids subtended between two of said reactive groups; exposing the peptide ligands to one or more cells which display one or more target molecules on the cell surface; and screening the peptide ligands for binding against the target, and selecting the ligands which bind to the target.Type: GrantFiled: April 24, 2018Date of Patent: April 2, 2024Assignee: BicycleRD LimitedInventors: Liuhong Chen, Michael Skynner, Amy Brown, James Cooke, Rachid Lani
-
Publication number: 20240083945Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the COVID-19 nucleocapsid protein (N-protein). The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by the COVID-19 nucleocapsid protein (N-protein), such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.Type: ApplicationFiled: January 10, 2022Publication date: March 14, 2024Inventors: Nicholas KEEN, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Yuliya DEMYDCHUK
-
Publication number: 20240083944Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.Type: ApplicationFiled: January 10, 2022Publication date: March 14, 2024Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
-
Patent number: 11904020Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.Type: GrantFiled: March 18, 2022Date of Patent: February 20, 2024Assignee: BicycleTx LimitedInventors: Paul Brennan, Amy Brown, Liuhong Chen, John Davis, Yuliya Demydchuk, Donatella Di Rienzo, Ellen Gowans, Rama McCrory, Emma Mead, Emma Murphy, Mike Rigby, Michael Skynner, Tom Smith, Steven Stanway
-
Publication number: 20240018508Abstract: The present invention relates to a method for determining an extent of cyclisation of a peptide ligand displayed on a genetic display system, wherein the peptide ligand comprises a polypeptide covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of exposing the polypeptide displayed on the genetic display system to the molecular scaffold, wherein said polypeptide comprises two or more peptide reactive groups on said two or more amino acid residues which form covalent bonds with the molecular scaffold at two or more scaffold reactive groups, to give the peptide ligand; removing unreacted molecular scaffold from the genetic display system; exposing the peptide ligand displayed on the genetic display system to a first probe, wherein the first probe binds to a first unconjugated reactive group on the peptide ligand; and measuring the first unconjugated reactive group on the peptide ligand.Type: ApplicationFiled: October 2, 2020Publication date: January 18, 2024Inventors: Michael SKYNNER, James COOKE, Emma CRAWLEY, Liuhong CHEN, Gemma MUDD, Paul BESWICK
-
Patent number: 11866518Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.Type: GrantFiled: April 6, 2021Date of Patent: January 9, 2024Assignee: BicycleTx LimitedInventors: Frank Narjes, Tor Svensson, Pavol Zlatoidsky, Lotta Hidestal, Liuhong Chen, Michael Skynner, Sophie Watcham
-
Publication number: 20230183291Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.Type: ApplicationFiled: May 14, 2021Publication date: June 15, 2023Inventors: Nicholas KEEN, Katerine VAN RIETSCHOTEN, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Yuliya DEMYDCHUK
-
Publication number: 20230106511Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs) more particularly PBP3. The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: February 26, 2021Publication date: April 6, 2023Inventors: Matthew BALMFORTH, Paul BESWICK, Liuhong CHEN, Mike DAWSON, Rachel DODS, Catherine ROWLAND, Michael SKYNNER, Katerine VAN RIETSCHOTEN
-
Patent number: 11613560Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.Type: GrantFiled: May 11, 2020Date of Patent: March 28, 2023Assignee: BicycleTx LimitedInventors: Tom Li Stephen, Kevin McDonnell, Nicholas Keen, Liuhong Chen, Helen Harrison, Peter U. Park, Michael Skynner, Harvey Che
-
Publication number: 20230086865Abstract: The present invention relates to a polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the bicyclic peptides of the invention are conjugated to a carrier peptide in order to greatly enhance the bacterial cell killing activity. More particularly, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs), such as PBP3 and PBP3a. The invention also includes pharmaceutical compositions comprising said conjugates and to the use of said conjugates in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: February 26, 2021Publication date: March 23, 2023Inventors: Matthew BALMFORD, Paul BESWICK, Mike DAWSON, Rachel DODS, Catherine ROWLAND, Michael SKYNNER, Katerine VANRIETSCHOTEN, James WAGSTAFF
-
Publication number: 20220363718Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.Type: ApplicationFiled: April 6, 2021Publication date: November 17, 2022Inventors: Frank NARJES, Tor SVENSSON, Pavol ZLATOIDSKY, Lotta HIDESTAL, Liuhong CHEN, Michael SKYNNER, Sophie WATCHAM
-
Publication number: 20220339289Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.Type: ApplicationFiled: April 20, 2022Publication date: October 27, 2022Inventors: Kevin MCDONNELL, Gemma MUDD, Michael SKYNNER, Sophie WATCHAM
-
Publication number: 20220296726Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.Type: ApplicationFiled: March 18, 2022Publication date: September 22, 2022Applicant: BicycleTx LimitedInventors: Paul Brennan, Amy Brown, Liuhong Chen, John Davis, Yuliya Demydchuk, Donatella Di Rienzo, Ellen Gowans, Rama McCrory, Emma Mead, Emma Murphy, Mike Rigby, Michael Skynner, Tom Smith, Steven Stanway
-
Publication number: 20220281918Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: August 28, 2020Publication date: September 8, 2022Inventors: Katerine VAN RIETSCHOTEN, Paul BESWICK, Mike DAWSON, Matthew BALMFORTH, Michael SKYNNER, Liuhong CHEN
-
Patent number: 11396530Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: October 28, 2020Date of Patent: July 26, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
-
Publication number: 20220194988Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: ApplicationFiled: November 12, 2021Publication date: June 23, 2022Inventors: Ellen GOWANS, Gemma Elizabeth MUDD, Michael RIGBY, Punit SETH, Michael SKYNNER, Steven STANWAY, Liudvikas URBONAS, Katerine VAN RIETSCHOTEN
-
Patent number: 11241473Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: September 2, 2020Date of Patent: February 8, 2022Assignee: BicycleTx LimitedInventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
-
Publication number: 20210147484Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: ApplicationFiled: October 28, 2020Publication date: May 20, 2021Inventors: Paul BESWICK, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner